Table I.
Descriptive statistics of testicular histology and treatment exposures for 32 boys who underwent testicular biopsy for fertility preservation and for 14 control samples from Karolinska Institutet’s internal biobank.
| Parameter | Chemotherapy | ||||
|---|---|---|---|---|---|
| Controls (biobank) | No chemotherapy | Hydroxyurea for SCD | Non-alkylating agents | Alkylating agents | |
| (n = 14) | (n = 12) | (n = 6) | (n = 8) | (n = 6) | |
| Age (y) | 5.6 ± 5.0 | 4.9 ± 3.1 | 7.9 ± 3.6 | 6.6 ± 4.8 | 7.3 ± 3.7 |
| Spermatogonia/cross-section | 4.1 ± 4.6 | 0.8 ± 0.9* | 0.3 ± 0.6*,## | 1.7 ± 1.0 | 0.2 ± 0.3*,## |
| Proportion of SCO tubules (%) | 40 ± 30 | 69 ± 21*,## | 90 ± 17*,## | 46 ± 18 | 89 ± 14*,## |
| Exposure to cyclophosphamide (g/m2) | 0 | 0 | 0 | 0 | 5.1 ± 3.2 |
| CED (g/m2) | 0 | 0 | 0 | 0 | 5.5 ± 3.0 |
| Cumulative anthracycline dose (mg/m2) | 0 | 0 | 0 | 161 ± 166 | 249 ± 118 |
| Hydroxyurea (mg/kg) | 0 | 0 | 24.5 ± 2.7 | 0 | 0 |
Abbreviations: CED, cumulative cyclophosphamide equivalent dose; SCO, Sertoli cell-only; SCD, sickle cell disease. *P < 0.05 when compared to value in control group, ##P < 0.05 when compared to value in group exposed to non-alkylating chemotherapy.